LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 20 of 497
Next
>>
>
476 to 500 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	Erlotinib	0.12	uM	LJP5	2	M23	72	hr	1097	3267	3769	0.8667	0.8119
BT-20	Erlotinib	0.12	uM	LJP5	3	M23	72	hr	1097	3439	3769	0.9123	0.8763
BT-20	Foretinib	0.12	uM	LJP5	1	H11	72	hr	1097	3599	3769	0.9548	0.9362
BT-20	Foretinib	0.12	uM	LJP5	2	H11	72	hr	1097	3617	3769	0.9595	0.9429
BT-20	Foretinib	0.12	uM	LJP5	3	H11	72	hr	1097	3689	3769	0.9786	0.9699
BT-20	R406	0.12	uM	LJP6	1	C17	72	hr	1097	3565	3769	0.9457	0.9235
BT-20	R406	0.12	uM	LJP6	2	C17	72	hr	1097	3558	3769	0.9439	0.9208
BT-20	R406	0.12	uM	LJP6	3	C17	72	hr	1097	3673	3769	0.9744	0.9639
BT-20	Pictilisib	0.12	uM	LJP6	1	D23	72	hr	1097	2594	3769	0.6882	0.5601
BT-20	Pictilisib	0.12	uM	LJP6	2	D23	72	hr	1097	2418	3769	0.6415	0.4942
BT-20	Pictilisib	0.12	uM	LJP6	3	D23	72	hr	1097	2718	3769	0.7210	0.6065
BT-20	Gefitinib	0.12	uM	LJP6	1	N11	72	hr	1097	3227	3769	0.8561	0.7970
BT-20	Gefitinib	0.12	uM	LJP6	2	N11	72	hr	1097	3190	3769	0.8463	0.7831
BT-20	Gefitinib	0.12	uM	LJP6	3	N11	72	hr	1097	3174	3769	0.8420	0.7771
BT-20	Geldanamycin	0.12	uM	LJP5	1	O05	72	hr	1097	1142	3769	0.3030	0.0167
BT-20	Geldanamycin	0.12	uM	LJP5	2	O05	72	hr	1097	1216	3769	0.3226	0.0444
BT-20	Geldanamycin	0.12	uM	LJP5	3	O05	72	hr	1097	1357	3769	0.3600	0.0972
BT-20	Geldanamycin	0.12	uM	LJP6	1	O05	72	hr	1097	1097	3769	0.2910	-0.0001
BT-20	Geldanamycin	0.12	uM	LJP6	2	O05	72	hr	1097	944	3769	0.2504	-0.0574
BT-20	Geldanamycin	0.12	uM	LJP6	3	O05	72	hr	1097	1108	3769	0.2939	0.0040
BT-20	GSK1059615	0.12	uM	LJP5	1	E05	72	hr	1097	2666	3769	0.7073	0.5870
BT-20	GSK1059615	0.12	uM	LJP5	2	E05	72	hr	1097	2941	3769	0.7802	0.6900
BT-20	GSK1059615	0.12	uM	LJP5	3	E05	72	hr	1097	2982	3769	0.7911	0.7053
BT-20	GSK1059615	0.12	uM	LJP6	1	C05	72	hr	1097	2447	3769	0.6492	0.5051
BT-20	GSK1059615	0.12	uM	LJP6	2	C05	72	hr	1097	2482	3769	0.6584	0.5182

|<
<<
Previous
Page 20 of 497
Next
>>
>
476 to 500 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)